E2F4-targeted Gene Therapy
Alzheimer's Disease
Key Facts
About Tetraneuron
Tetraneuron is a private, preclinical-stage biotech company pioneering a novel gene therapy platform targeting the E2F4 protein to address neurodegenerative diseases. The company, spun from research at Spain's prestigious Cajal Institute, is advancing a multifactorial approach aimed at reversing disease pathology. Having completed key preclinical milestones, including regulatory interactions and NHP GLP studies, and secured seed funding, Tetraneuron is positioning to advance its lead programs toward clinical development. Its strategy targets the vast, underserved market of Alzheimer's and Parkinson's diseases with a potentially disease-modifying therapy.
View full company profileAbout Tetraneuron
Tetraneuron is a private, preclinical-stage biotech company pioneering a novel gene therapy platform targeting the E2F4 protein to address neurodegenerative diseases. The company, spun from research at Spain's prestigious Cajal Institute, is advancing a multifactorial approach aimed at reversing disease pathology. Having completed key preclinical milestones, including regulatory interactions and NHP GLP studies, and secured seed funding, Tetraneuron is positioning to advance its lead programs toward clinical development. Its strategy targets the vast, underserved market of Alzheimer's and Parkinson's diseases with a potentially disease-modifying therapy.
View full company profileTherapeutic Areas
Other Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |